Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tacoma, WA
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Vancouver, WA
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Vancouver, WA
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Yakima, WA
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Yakima, WA
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Green Bay, WI
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Green Bay, WI
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Janesville, WI
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Janesville, WI
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Milwaukee, WI
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Quilmes,
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Quilmes,
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Poughkeepsie, NY
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Mount Sterling, KY
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Mount Sterling, KY
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Santa Fe, NM
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
The Woodlands, TX
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Washington,
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis
4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis
Status: Enrolling
Updated:  12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis
4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis
Status: Enrolling
Updated: 12/31/1969
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Ocala Oncology Center
mi
from
Ocala, FL
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Ocala Oncology Center
mi
from
Ocala, FL
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of Florida
mi
from
Ocoee, FL
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of Florida
mi
from
Ocoee, FL
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of North Carolina
mi
from
Raleigh, NC
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of North Carolina
mi
from
Raleigh, NC
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Arlington South
mi
from
Arlington, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Arlington South
mi
from
Arlington, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A. - Bedford
mi
from
Bedford, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Texas Cancer Center of Mesquite
mi
from
Mesquite, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology and Hematology, PA
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Willamette Valley Cancer Institute/Research Ctr
mi
from
Eugene, OR
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Willamette Valley Cancer Institute/Research Ctr
mi
from
Eugene, OR
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Cancer Care And Research Center
mi
from
Waco, TX
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Cancer Care And Research Center
mi
from
Waco, TX
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated:  12/31/1969
Yakima Valley Mem Hosp/North Star Lodge
mi
from
Yakima, WA
Sunitinib Non Small Cell Lung Cancer Patients Over 70
Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70
Status: Enrolling
Updated: 12/31/1969
Yakima Valley Mem Hosp/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors
Study of Automated Abdominal Compression Device and Screw Based Abdominal Compression Devices During Stereotactic Body Radiation Therapy of Lung Tumors
Status: Enrolling
Updated:  12/31/1969
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors
Study of Automated Abdominal Compression Device and Screw Based Abdominal Compression Devices During Stereotactic Body Radiation Therapy of Lung Tumors
Status: Enrolling
Updated: 12/31/1969
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Atlanta, GA
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Albuquerque, NM
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Cincinnati, OH
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Anniston, AL
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Anniston, AL
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
La Jolla, CA
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Orange, CA
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Orlando, FL
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
Chicago, IL
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
ImClone Investigational Site
mi
from
New York, NY
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Randomized, Open Label, Stratified Phase 2 Trial of Gemcitabine, Carboplatin, and Cetuximab With Vs. Without IMC-A12 in Chemotherapy-Naive Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
ImClone Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
Regional Medical Center
mi
from
Anniston, AL
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Regional Medical Center
mi
from
Anniston, AL
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
Providence Cancer Center at Providence Hospital
mi
from
Mobile, AL
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Providence Cancer Center at Providence Hospital
mi
from
Mobile, AL
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
Providence Cancer Center
mi
from
Anchorage, AK
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Providence Cancer Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
NEA Medical Clinic - East Matthews
mi
from
Jonesboro, AR
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
NEA Medical Clinic - East Matthews
mi
from
Jonesboro, AR
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
East Bay Radiation Oncology Center
mi
from
Castro Valley, CA
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
East Bay Radiation Oncology Center
mi
from
Castro Valley, CA
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
Valley Medical Oncology Consultants - Castro Valley
mi
from
Castro Valley, CA
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Valley Medical Oncology Consultants - Castro Valley
mi
from
Castro Valley, CA
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
Cancer Care Center at John Muir Health - Concord Campus
mi
from
Concord, CA
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Cancer Care Center at John Muir Health - Concord Campus
mi
from
Concord, CA
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
North Bay Cancer Center
mi
from
Fairfield, CA
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
North Bay Cancer Center
mi
from
Fairfield, CA
Click here to add this to my saved trials
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated:  12/31/1969
Valley Medical Oncology
mi
from
Fremont, CA
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
Status: Enrolling
Updated: 12/31/1969
Valley Medical Oncology
mi
from
Fremont, CA
Click here to add this to my saved trials